Dalpiciclib 125mg

DRUG3 trials

Sponsors

wanghaibo, Fujian Cancer Hospital, Tang-Du Hospital

Conditions

Breast CancerBreast DiseasesBreast NeoplasmsCDK4/6 InhibitorDalpiciclibEndocrine Breast DiseasesHR Positive HER2 Negative Advanced Breast CancerHR Positive/HER2 Low Breast Cancer

Phase 2

Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer

RecruitingNCT07285382

wanghaiboHR Positive HER2 Negative Advanced Breast Cancer

Start: 2025-06-25End: 2028-12-31Target: 120Updated: 2025-12-16

Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study

RecruitingNCT07581834

Fujian Cancer HospitalBreast Diseases, Breast Neoplasms, CDK4/6 Inhibitor +3

Start: 2026-01-21End: 2032-06-30Target: 2000Updated: 2026-05-12

Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast Cancer

Not yet recruitingNCT07618923

Tang-Du HospitalBreast Cancer, HR Positive/HER2 Low Breast Cancer

Start: 2026-06-01End: 2029-01-01Target: 20Updated: 2026-06-11